B+
Bull case
30%
Probability
Target price
$15.50
+93.8% vs current
ARVN
ArvinasCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$11.00
+37.5% vs current
B-
Bear case
25%
Probability
Target price
$6.50
-18.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+89.8
Score
AI commentary
T+3 earnings follow-up reads mixed-to-constructive rather than decisively bullish. The company source delivered an approval-plus-pipeline update and reaffirmed runway into 2H28 [#8-K-2026-05-12], while secondary post-print coverage showed several upward target revisions. Even so, the tape still looks unstable: StockAnalysis showed ARVN at $9.42 on May 14, 2026, down 4.56% that day, which suggests investors have not fully capitalized the approval and licensing news. Analyst revision breadth remains limited, and no reliable social signal was provided in the packet, so this stays a cautious monitoring setup.
RankAlpha Sentiment Codex - 2026-05-15
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-13eventARV-102 regulatory feedback and added biomarker data are the key 2H26 pipeline readoutHigh impact
Management guided to a Phase 1b PSP start for ARV-102 upon FDA clearance and to additional Parkinson’s biomarker data in 2H26 after reporting >50% LRRK2 degradation in CSF and biomarker modulation in Phase 1; this is the clearest program-level value inflection beyond VEPPANU [#8-K-2026-05-12].
2026-08-13catalystVEPPANU out-licensing close with Rigel could crystallize near-term economicsHigh impact
Arvinas said VEPPANU was approved, then licensed with Pfizer to Rigel, with closing still subject to consents and HSR clearance; the same earnings update also highlighted VEPPANU’s NCCN inclusion, making deal close and early commercialization optics the nearest tangible post-approval checkpoint [#8-K-2026-05-12].
2027-05-15catalystMultiple 2026 early-stage oncology readouts can test whether Arvinas remains a platform storyHigh impact
The company said ARV-806 should enter dose expansion and produce initial 2026 data, ARV-393 should post updated Phase 1 data in 2H26, and ARV-6723 is planned to enter Phase 1 in mid-2026; success would broaden the story beyond vepdegestrant, while slippage would reinforce a monitoring stance [#8-K-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology